Karyopharm Therapeutics Inc (KPTI) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Karyopharm Therapeutics Inc   (NASDAQ: KPTI)
 

Karyopharm Therapeutics Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

According to the latest Balance sheet Jun 30 2026, Karyopharm Therapeutics Inc has not recorded any inventories.
Visit Karyopharm Therapeutics Inc Balance sheet

Within Healthcare sector 288 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1496 in the first quarter 2026, to 1743.

KPTI Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Karyopharm Therapeutics Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KPTI Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth -19.99 % -24.53 % -14.79 % -15.11 % 43.61 %
Y / Y Cost of Sales Growth - 3.38 % 11.5 % 62.54 % -28.26 %
Inventory Turnover Ratio (TTM) - 1.44 1.34 1.26 1.04
KPTI's Total Ranking # 1743 # 1496 # 844 # 1117 # 1524
Average inventory processing period - 253 272 291 351
Seq. Inventory Growth 10.98 % -10.87 % 1.82 % -20.55 % 4.68 %
Seq. Cost of Sales Growth - -9.37 % -29.77 % 101.05 % -19.22 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 289
Overall Market # 1743

Inventory Turnover Ratio Statistics
High Average Low
2.64 1.13 0.03
(Jun 30 2020)   (Mar 31 2021)



KPTI Company Profile >> Back to KPTI Efficiency Comparisons >> Compare KPTI Inventory Turnover Ratio to its Competitors

Financial Statements
Karyopharm Therapeutics Inc 's Inventories $ 4 Millions Visit KPTI's Balance sheet
Karyopharm Therapeutics Inc 's Cost of Revenues TTM $ 5 Millions Visit KPTI's Income Statement
What are KPTI's Sales? Visit KPTI's Sales by Segment

Other Inventory Turnover Ratios
Karyopharm Therapeutics Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
KPTI's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for KPTI's Competitors
Inventory Turnover Ratio for KPTI's Suppliers
Inventory Turnover Ratio for KPTI's Customers

You may also want to know
KPTI's Sales Growth Rates KPTI's Pe Price to earnings ratio KPTI's Receivables Turnover Ratio KPTI's Stock Quote
KPTI's Net Income Growth Rates KPTI's Ps Price to Sales ratio KPTI's Sales per Employee KPTI's Asset Turnover Ratio
KPTI's Net Margin KPTI's Pb Price to Book ratio KPTI's Financial Strength Ratios KPTI's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Mirum Pharmaceuticals Inc   3.40 $ 85.221  Millions$ 25  Millions
Zai Lab Limited  3.39 $ 195.542  Millions$ 58  Millions
Cadre Holdings inc   3.39 $ 399.991  Millions$ 118  Millions
Bausch Health Companies Inc   3.38 $ 3,783.000  Millions$ 1,120  Millions
Bellevue Life Sciences Acquisition Corp  3.38 $ 1.215  Millions$ 0  Millions
Evolus Inc   3.37 $ 105.904  Millions$ 31  Millions
Gilead Sciences Inc   3.35 $ 6,217.000  Millions$ 1,857  Millions
10x Genomics Inc   3.29 $ 184.539  Millions$ 56  Millions
Exelixis Inc   3.28 $ 85.665  Millions$ 26  Millions
Biofrontera Inc   3.28 $ 6.622  Millions$ 2  Millions
Becton Dickinson And Company  3.25 $ 11,161.000  Millions$ 3,429  Millions
Maravai Lifesciences Holdings Inc   3.22 $ 135.038  Millions$ 42  Millions
Solventum Corporation  3.22 $ 3,421.000  Millions$ 1,061  Millions
Agilent Technologies inc   3.20 $ 3,404.000  Millions$ 1,064  Millions
Mettler toledo International Inc   3.18 $ 1,277.460  Millions$ 401  Millions
Bionexus Gene Lab Corp   3.15 $ 2.362  Millions$ 1  Millions
Zevra Therapeutics Inc   3.14 $ 6.180  Millions$ 2  Millions
Prestige Consumer Healthcare Inc   3.13 $ 513.522  Millions$ 164  Millions
Eton Pharmaceuticals Inc   3.11 $ 44.176  Millions$ 14  Millions
Iovance Biotherapeutics inc   3.09 $ 167.681  Millions$ 54  Millions
Mimedx Group Inc   3.07 $ 75.981  Millions$ 25  Millions
Revvity Inc  2.98 $ 1,136.473  Millions$ 381  Millions
Amneal Pharmaceuticals Inc   2.98 $ 1,891.689  Millions$ 635  Millions
Akebia Therapeutics Inc   2.96 $ 44.632  Millions$ 15  Millions
Msa Safety Inc  2.92 $ 1,021.036  Millions$ 350  Millions
Ligand Pharmaceuticals Incorporated  2.91 $ 32.387  Millions$ 11  Millions
Logicmark Inc  2.83 $ 3.881  Millions$ 1  Millions
Dexcom Inc   2.81 $ 1,864.400  Millions$ 663  Millions
Livanova Plc  2.79 $ 468.065  Millions$ 168  Millions
Merck and Co Inc   2.79 $ 17,996.000  Millions$ 6,447  Millions

Date modified: 2026-10-05T11:03:41+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.